Holen Sie sich die Stockscreener-App
13.15
0.19%
-0.025
Schlusskurs vom Vortag:
$13.18
Offen:
$13.11
24-Stunden-Volumen:
2.03M
Relative Volume:
0.68
Marktkapitalisierung:
$1.87B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-412.89M
KGV:
-3.4067
EPS:
-3.86
Netto-Cashflow:
$-361.93M
1W Leistung:
-7.52%
1M Leistung:
+13.17%
6M Leistung:
+6.39%
1J Leistung:
-60.24%
1-Tages-Spanne:
$13.07
$13.68
1-Wochen-Bereich:
$12.62
$14.22
52-Wochen-Spanne:
$6.36
$37.08
Dyne Therapeutics Inc Stock (DYN) Company Profile
Firmenname
Dyne Therapeutics Inc
Sektor
Branche
Telefon
(781) 786-8230
Adresse
1560 TRAPELO ROAD, WALTHAM
Vergleichen Sie DYN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
13.15 | 1.89B | 0 | -412.89M | -361.93M | -3.86 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-25 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2025-06-24 | Eingeleitet | Bernstein | Mkt Perform |
| 2025-06-11 | Fortgesetzt | Raymond James | Outperform |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-29 | Eingeleitet | Evercore ISI | Outperform |
| 2025-03-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-12-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-26 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-10-24 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-05-21 | Bestätigt | Chardan Capital Markets | Buy |
| 2024-04-30 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-02-27 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-02-15 | Eingeleitet | Oppenheimer | Outperform |
| 2023-01-26 | Eingeleitet | Guggenheim | Buy |
| 2022-07-20 | Eingeleitet | Chardan Capital Markets | Buy |
| 2022-07-12 | Eingeleitet | Raymond James | Outperform |
| 2020-10-12 | Eingeleitet | JP Morgan | Overweight |
| 2020-10-12 | Eingeleitet | Jefferies | Buy |
| 2020-10-12 | Eingeleitet | Piper Sandler | Overweight |
| 2020-10-12 | Eingeleitet | Stifel | Buy |
Alle ansehen
Dyne Therapeutics Inc Aktie (DYN) Neueste Nachrichten
59,673 Shares in Dyne Therapeutics, Inc. $DYN Purchased by Voleon Capital Management LP - MarketBeat
Graham Capital Management L.P. Makes New Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics (NASDAQ:DYN) CEO John Cox Sells 2,640 Shares - MarketBeat
Brokerages Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Target Price at $34.07 - MarketBeat
Exome Asset Management LLC Acquires Shares of 258,391 Dyne Therapeutics, Inc. $DYN - MarketBeat
Invesco Ltd. Has $693,000 Stock Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating - Yahoo Finance
Dyne therapeutics CMO Kerr sells shares worth $59k By Investing.com - Investing.com Canada
Dyne Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Dyne Therapeutics, Inc. $DYN Shares Acquired by Trexquant Investment LP - MarketBeat
224,176 Shares in Dyne Therapeutics, Inc. $DYN Bought by PDT Partners LLC - MarketBeat
RA Capital Management L.P. Buys 3,333,248 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Frazier Life Sciences Management L.P. Makes New $15.10 Million Investment in Dyne Therapeutics, Inc. $DYN - MarketBeat
Will Dyne Therapeutics Inc. outperform the market2025 Price Momentum & Free Growth Oriented Trading Recommendations - Newser
Trend analysis for Dyne Therapeutics Inc. this week2025 Institutional Moves & Growth Focused Stock Pick Reports - Newser
Market reaction to Dyne Therapeutics Inc.’s recent newsInsider Selling & Technical Entry and Exit Tips - Newser
ADAR1 Capital Management LLC Buys Shares of 30,099 Dyne Therapeutics, Inc. $DYN - MarketBeat
Rafferty Asset Management LLC Sells 20,129 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Can Dyne Therapeutics Inc. benefit from deglobalizationJuly 2025 Catalysts & Low Drawdown Momentum Ideas - خودرو بانک
Can Dyne Therapeutics Inc. be recession proofJuly 2025 Pullbacks & Intraday High Probability Alerts - خودرو بانک
Will Dyne Therapeutics Inc. stock recover after recent dropGap Down & Free Real-Time Volume Trigger Notifications - Newser
Dyne Therapeutics, Inc. $DYN Shares Bought by Armistice Capital LLC - MarketBeat
Chart based analysis of Dyne Therapeutics Inc. trendsMarket Movement Recap & Reliable Breakout Forecasts - Newser
Will Dyne Therapeutics Inc. benefit from government policyWeekly Trade Summary & Daily Stock Trend Reports - خودرو بانک
Can Dyne Therapeutics Inc. navigate macro headwindsCPI Data & AI Based Buy and Sell Signals - خودرو بانک
What is the dividend yield of Dyne Therapeutics Inc.2025 Major Catalysts & Accurate Trade Setup Notifications - خودرو بانک
Is Dyne Therapeutics Inc. meeting your algorithmic filter criteria2025 Market Outlook & Daily Profit Maximizing Trade Tips - Newser
Dyne Therapeutics Inc. stock prediction for this week2025 Price Targets & AI Enhanced Trading Signals - Newser
Russell Investments Group Ltd. Has $710,000 Stock Holdings in Dyne Therapeutics, Inc. $DYN - MarketBeat
How to use Fibonacci retracement on Dyne Therapeutics Inc.Earnings Overview Summary & Weekly Sector Rotation Insights - Newser
Will Dyne Therapeutics Inc. benefit from macro trendsJuly 2025 Institutional & Risk Controlled Daily Plans - Newser
Custom watchlist performance reports with Dyne Therapeutics Inc.Dollar Strength & Low Drawdown Momentum Ideas - Newser
Is it time to cut losses on Dyne Therapeutics Inc.2025 Growth vs Value & AI Based Buy/Sell Signal Reports - Newser
Intraday pattern recognizer results for Dyne Therapeutics Inc.July 2025 Short Interest & Weekly Breakout Watchlists - Newser
Morgan Stanley Reiterates a Buy Rating on Dyne Therapeutics (DYN), Keeps the PT - MSN
Can Dyne Therapeutics Inc. expand its profit marginsJuly 2025 Closing Moves & Breakout Confirmation Trade Signals - خودرو بانک
Live market analysis of Dyne Therapeutics Inc.Weekly Trade Review & Risk Managed Investment Entry Signals - Newser
Key metrics from Dyne Therapeutics Inc.’s quarterly dataJuly 2025 Analyst Calls & AI Powered Buy and Sell Recommendations - Newser
Should you hold or exit Dyne Therapeutics Inc. nowWeekly Stock Summary & Short-Term Trading Opportunity Alerts - Newser
Tick level data insight on Dyne Therapeutics Inc. volatilityLayoff News & Free Technical Confirmation Trade Alerts - Newser
Dyne Therapeutics, Inc. $DYN Shares Purchased by Siren L.L.C. - MarketBeat
Will Dyne Therapeutics Inc. continue its uptrendMarket Sentiment Report & High Accuracy Swing Entry Alerts - Newser
Pattern recognition hints at Dyne Therapeutics Inc. upsideQuarterly Market Summary & Expert Approved Momentum Ideas - Newser
Using fundamentals and technicals on Dyne Therapeutics Inc.July 2025 Sector Moves & Growth Focused Stock Reports - Newser
Is Dyne Therapeutics Inc. forming a double bottomProfit Target & Fast Momentum Stock Entry Tips - beatles.ru
Is Dyne Therapeutics Inc. still worth holding after the dipWeekly Profit Report & Free Low Drawdown Momentum Trade Ideas - Newser
Finanzdaten der Dyne Therapeutics Inc-Aktie (DYN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Dyne Therapeutics Inc-Aktie (DYN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Friedl-Naderer Johanna | Chief Commercial Officer |
Sep 04 '25 |
Sale |
13.27 |
894 |
11,863 |
95,017 |
| Friedl-Naderer Johanna | Chief Commercial Officer |
Sep 05 '25 |
Sale |
13.41 |
144 |
1,931 |
94,873 |
| Kerr Douglas | Chief Medical Officer |
Sep 04 '25 |
Sale |
13.27 |
3,552 |
47,135 |
89,263 |
| Kerr Douglas | Chief Medical Officer |
Sep 05 '25 |
Sale |
13.41 |
873 |
11,707 |
88,390 |
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):